Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine

Christian Ott, Susanne Jung, Manuel Korn, Dennis Kannenkeril, Agnes Bosch, Julie Kolwelter, Kristina Striepe, Peter Bramlage, Mario Schiffer, Roland E Schmieder, Christian Ott, Susanne Jung, Manuel Korn, Dennis Kannenkeril, Agnes Bosch, Julie Kolwelter, Kristina Striepe, Peter Bramlage, Mario Schiffer, Roland E Schmieder

Abstract

Background: Type 2 diabetes causes cardio-renal complications and is treated with different combination therapies. The renal hemodynamics profile of such combination therapies has not been evaluated in detail.

Methods: Patients (N = 97) with type 2 diabetes were randomized to receive either empagliflozin and linagliptin (E+L group) or metformin and insulin glargine (M+I group) for 3 months. Renal hemodynamics were assessed with para-aminohippuric acid and inulin for renal plasma flow (RPF) and glomerular filtration rate (GFR). Intraglomerular hemodynamics were calculated according the Gomez´ model.

Results: Treatment with E+L reduced GFR (p = 0.003), but RPF remained unchanged (p = 0.536). In contrast, M+I not only reduced GFR (p = 0.001), but also resulted in a significant reduction of RPF (p < 0.001). Renal vascular resistance (RVR) decreased with E+L treatment (p = 0.001) but increased with M+I treatment (p = 0.001). The changes in RPF and RVR were different between the two groups (both padjust < 0.001). Analysis of intraglomerular hemodynamics revealed that E+L did not change resistance of afferent arteriole (RA) (p = 0.116), but diminished resistance of efferent arterioles (RE) (p = 0.001). In M+I group RA was increased (p = 0.006) and RE remained unchanged (p = 0.538). The effects on RA (padjust < 0.05) and on RE (padjust < 0.05) differed between the groups.

Conclusions: In patients with type 2 diabetes and preserved renal function treatment with M+I resulted in reduction of renal perfusion and increase in vascular resistance, in contrast to treatment with E+I that preserved renal perfusion and reduced vascular resistance. Moreover, different underlying effects on the resistance vessels have been estimated according to the Gomez model, with M+I increasing RA and E+L predominantly decreasing RE, which is in contrast to the proposed sodium-glucose cotransporter 2 inhibitor effects.

Trial registration: The study was registered at www.clinicaltrials.gov (NCT02752113) on April 26, 2016.

Keywords: Hemodynamics; Intraglomerular; Renal; Type 2 diabetes.

Conflict of interest statement

PB received research funding from Boehringer for this and other studies; RES has received speaker fees and advisory board fees from Boehringer Ingelheim Pharma GmbH & Co KG.

© 2021. The Author(s).

Figures

Fig. 1
Fig. 1
Treatment-induced percent change of renal and intraglomerular hemodynamics

References

    1. Global Burden of Metabolic Risk Factors for Chronic Diseases Cardiovascular disease, chronic kidney disease, and diabetes mortality burden of cardiometabolic risk factors from 1980 to 2010: a comparative risk assessment. Lancet Diabetes Endocrinol. 2014;2(8):634–47. doi: 10.1016/S2213-8587(14)70102-0.
    1. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2015;58(3):429–42. doi: 10.1007/s00125-014-3460-0.
    1. Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetologia. 2018;61(12):2461–98. doi: 10.1007/s00125-018-4729-5.
    1. Tonneijck L, Muskiet MH, Smits MM, van Bommel EJ, Heerspink HJ, van Raalte DH, et al. Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment. J Am Soc Nephrol. 2017;28(4):1023–1039. doi: 10.1681/ASN.2016060666.
    1. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851–860. doi: 10.1056/NEJMoa011303.
    1. Brenner BM, Hostetter TH, Olson JL, Rennke HG, Venkatachalam MA. The role of glomerular hyperfiltration in the initiation and progression of diabetic nephropathy. Acta Endocrinol Suppl. 1981;242:7–10.
    1. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128. doi: 10.1056/NEJMoa1504720.
    1. Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323–334. doi: 10.1056/NEJMoa1515920.
    1. Giugliano D, De Nicola L, Maiorino MI, Bellastella G, Garofalo C, Chiodini P, et al. Preventing major adverse cardiovascular events by SGLT-2 inhibition in patients with type 2 diabetes: the role of kidney. Cardiovasc Diabetol. 2020;19(1):35. doi: 10.1186/s12933-020-01010-x.
    1. Giorgino F, Vora J, Fenici P, Solini A. Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk. Cardiovasc Diabetol. 2020;19(1):196. doi: 10.1186/s12933-020-01163-9.
    1. Yamada T, Wakabayashi M, Bhalla A, Chopra N, Miyashita H, Mikami T, et al. Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis. Cardiovasc Diabetol. 2021;20(1):14. doi: 10.1186/s12933-020-01197-z.
    1. Denic A, Mathew J, Lerman LO, Lieske JC, Larson JJ, Alexander MP, et al. Single-nephron glomerular filtration rate in healthy adults. N Engl J Med. 2017;376(24):2349–2357. doi: 10.1056/NEJMoa1614329.
    1. Arakawa K, Ishihara T, Oku A, Nawano M, Ueta K, Kitamura K, et al. Improved diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the Na(+)-glucose cotransporter inhibitor T-1095. Br J Pharmacol. 2001;132(2):578–586. doi: 10.1038/sj.bjp.0703829.
    1. Cherney DZ, Perkins BA, Soleymanlou N, Maione M, Lai V, Lee A, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014;129(5):587–597. doi: 10.1161/CIRCULATIONAHA.113.005081.
    1. van Bommel EJM, Muskiet MHA, van Baar MJB, Tonneijck L, Smits MM, Emanuel AL, et al. The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial. Kidney Int. 2020;97(1):202–212. doi: 10.1016/j.kint.2019.09.013.
    1. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group. Kidney international. 1995;47(6):1703–20.
    1. Erpeldinger S, Rehman MB, Berkhout C, Pigache C, Zerbib Y, Regnault F, et al. Efficacy and safety of insulin in type 2 diabetes: meta-analysis of randomised controlled trials. BMC Endocr Disord. 2016;16(1):39. doi: 10.1186/s12902-016-0120-z.
    1. Jung S, Bosch A, Kannenkeril D, Karg MV, Striepe K, Bramlage P, et al. Combination of empagliflozin and linagliptin improves blood pressure and vascular function in type 2 diabetes. J Eur Heart J Cardiovasc Pharmacother. 2020;6(6):364–371. doi: 10.1093/ehjcvp/pvz078.
    1. Schmieder RE, Gatzka C, Schobel H, Schachinger H, Weihprecht H. Renal hemodynamic response to stress is influenced by ACE-inhibitors. Clin Nephrol. 1994;42(6):381–388.
    1. Delles C, Klingbeil AU, Schneider MP, Handrock R, Schaufele T, Schmieder RE. The role of nitric oxide in the regulation of glomerular haemodynamics in humans. Nephrol Dial transpl. 2004;19(6):1392–1397. doi: 10.1093/ndt/gfh187.
    1. Ott C, Schneider MP, Delles C, Schlaich MP, Schmieder RE. Reduction in basal nitric oxide activity causes albuminuria. Diabetes. 2011;60(2):572–576. doi: 10.2337/db09-1630.
    1. Smith HW, Finkelstein N, Aliminosa L, Crawford B, Graber M. The renal clearances of substituted hippuric acid derivatives and other aromatic acids in dog and man. J Clin Investig. 1945;24(3):388–404. doi: 10.1172/JCI101618.
    1. Gomez DM. Evaluation of renal resistances, with special reference to changes in essential hypertension. J Clin Investig. 1951;30(10):1143–1155. doi: 10.1172/JCI102534.
    1. Guidi E, Cozzi MG, Minetti EE, Civati G, Busnach G, Brando B. Effect of familial hypertension on glomerular hemodynamics and tubulo-glomerular feedback after uninephrectomy. Am J Hypertens. 2001;14(2):121–128. doi: 10.1016/S0895-7061(00)01238-3.
    1. Ott C, Ritt M, Titze SI, Schaufele T, Schmieder RE. Rosuvastatin does not affect intrarenal hemodynamics in patients with hypercholesterolemia. J Nephrol. 2009;22(5):675–681.
    1. Ott C, Schneider MP, Raff U, Ritt M, Striepe K, Alberici M, et al. Effects of manidipine vs. amlodipine on intrarenal haemodynamics in patients with arterial hypertension. Br J Clin Pharmacol. 2013;75(1):129–35. doi: 10.1111/j.1365-2125.2012.04336.x.
    1. Ott C, Kistner I, Keller M, Friedrich S, Willam C, Bramlage P, et al. Effects of linagliptin on renal endothelial function in patients with type 2 diabetes: a randomised clinical trial. Diabetologia. 2016;59(12):2579–2587. doi: 10.1007/s00125-016-4083-4.
    1. Cohen AJ, McCarthy DM, Stoff JS. Direct hemodynamic effect of insulin in the isolated perfused kidney. Am J Physiol. 1989;257(4 Pt 2):F580–F585.
    1. Juncos LA, Ito S. Disparate effects of insulin on isolated rabbit afferent and efferent arterioles. J Clin Investig. 1993;92(4):1981–1985. doi: 10.1172/JCI116792.
    1. Kidokoro K, Cherney DZI, Bozovic A, Nagasu H, Satoh M, Kanda E, et al. Evaluation of glomerular hemodynamic function by empagliflozin in diabetic mice using in vivo imaging. Circulation. 2019;140(4):303–315. doi: 10.1161/CIRCULATIONAHA.118.037418.
    1. Skrtic M, Yang GK, Perkins BA, Soleymanlou N, Lytvyn Y, von Eynatten M, et al. Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration. Diabetologia. 2014;57(12):2599–2602. doi: 10.1007/s00125-014-3396-4.
    1. Klessens CQ, Woutman TD, Veraar KA, Zandbergen M, Valk EJ, Rotmans JI, et al. An autopsy study suggests that diabetic nephropathy is underdiagnosed. Kidney Int. 2016;90(1):149–156. doi: 10.1016/j.kint.2016.01.023.
    1. Tonneijck L, Smits MM, Muskiet MH, Hoekstra T, Kramer MH, Danser AH, et al. Renal effects of DPP-4 inhibitor sitagliptin or GLP-1 receptor agonist liraglutide in overweight patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled trial. Diabetes Care. 2016;39(11):2042–2050. doi: 10.2337/dc16-1371.
    1. Muskiet MHA, Tonneijck L, Smits MM, Kramer MHH, Ouwens DM, Hartmann B, et al. Effects of DPP-4 inhibitor linagliptin versus sulfonylurea glimepiride as add-on to metformin on renal physiology in overweight patients with type 2 diabetes (RENALIS): a randomized double-blind trial. Diabetes Care. 2020;43(11):2889–2893. doi: 10.2337/dc20-0902.
    1. Bjornstad P, Skrtic M, Lytvyn Y, Maahs DM, Johnson RJ, Cherney DZ. The Gomez' equations and renal hemodynamic function in kidney disease research. Am J Physiol Renal Physiol. 2016;311(5):F967–F975. doi: 10.1152/ajprenal.00415.2016.
    1. Cooper ME, Inzucchi SE, Zinman B, Hantel S, von Eynatten M, Wanner C, et al. Glucose control and the effect of empagliflozin on kidney outcomes in type 2 diabetes: an analysis from the EMPA-REG OUTCOME trial. Am J Kidney Dis. 2019;74(5):713–715. doi: 10.1053/j.ajkd.2019.03.432.
    1. Zhang Y, Nakano D, Guan Y, Hitomi H, Uemura A, Masaki T, et al. A sodium-glucose cotransporter 2 inhibitor attenuates renal capillary injury and fibrosis by a vascular endothelial growth factor-dependent pathway after renal injury in mice. Kidney Int. 2018;94(3):524–535. doi: 10.1016/j.kint.2018.05.002.
    1. Heerspink HJL, Perco P, Mulder S, Leierer J, Hansen MK, Heinzel A, et al. Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease. Diabetologia. 2019;62(7):1154–1166. doi: 10.1007/s00125-019-4859-4.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa